Anavex Life Sciences Corp has a consensus price target of $33 based on the ratings of 5 analysts. The high is $46 issued by EF Hutton on July 22, 2024. The low is $11 issued by Cantor Fitzgerald on December 6, 2022. The 3 most-recent analyst ratings were released by EF Hutton, HC Wainwright & Co., and HC Wainwright & Co. on July 22, 2024, June 11, 2024, and May 10, 2024, respectively. With an average price target of $42 between EF Hutton, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 550.07% upside for Anavex Life Sciences Corp from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
07/22/2024 | Buy Now | 611.99% | EF Hutton | Jason Kolbert | → $46 | Initiates | → Buy | Get Alert |
06/11/2024 | Buy Now | 519.12% | HC Wainwright & Co. | Raghuram Selvaraju | $40 → $40 | Reiterates | Buy → Buy | Get Alert |
05/10/2024 | Buy Now | 519.12% | HC Wainwright & Co. | Raghuram Selvaraju | → $40 | Reiterates | Buy → Buy | Get Alert |
01/03/2024 | Buy Now | 519.12% | HC Wainwright & Co. | Raghuram Selvaraju | $54 → $40 | Maintains | Buy | Get Alert |
11/28/2023 | Buy Now | 735.81% | HC Wainwright & Co. | Raghuram Selvaraju | → $54 | Reiterates | Buy → Buy | Get Alert |
08/08/2023 | Buy Now | 735.81% | HC Wainwright & Co. | Raghuram Selvaraju | → $54 | Reiterates | Buy → Buy | Get Alert |
07/20/2023 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju | — | Reiterates | Buy → Buy | Get Alert |
06/29/2023 | Buy Now | 735.81% | HC Wainwright & Co. | Raghuram Selvaraju | → $54 | Reiterates | Buy → Buy | Get Alert |
05/02/2023 | Buy Now | 735.81% | HC Wainwright & Co. | Raghuram Selvaraju | → $54 | Reiterates | → Buy | Get Alert |
03/31/2023 | Buy Now | 735.81% | HC Wainwright & Co. | Raghuram Selvaraju | $50 → $54 | Maintains | Buy | Get Alert |
02/09/2023 | Buy Now | 333.38% | BTIG | Yun Zhong | $35 → $28 | Maintains | Buy | Get Alert |
02/09/2023 | Buy Now | 673.9% | HC Wainwright & Co. | Raghuram Selvaraju | → $50 | Reiterates | → Buy | Get Alert |
02/06/2023 | Buy Now | 673.9% | HC Wainwright & Co. | Raghuram Selvaraju | → $50 | Reiterates | → Buy | Get Alert |
01/03/2023 | Buy Now | 673.9% | HC Wainwright & Co. | Raghuram Selvaraju | $42 → $50 | Maintains | Buy | Get Alert |
12/06/2022 | Buy Now | 70.26% | Cantor Fitzgerald | Charles Duncan | $16 → $11 | Downgrade | Overweight → Neutral | Get Alert |
06/23/2022 | Buy Now | 519.12% | Berenberg | Caroline Palomeque | → $40 | Initiates | → Buy | Get Alert |
02/02/2022 | Buy Now | 550.07% | HC Wainwright & Co. | Raghuram Selvaraju | $39 → $42 | Maintains | Buy | Get Alert |
09/23/2021 | Buy Now | 441.73% | BTIG | Yun Zhong | — | Initiates | → Buy | Get Alert |
The latest price target for Anavex Life Sciences (NASDAQ:AVXL) was reported by EF Hutton on July 22, 2024. The analyst firm set a price target for $46.00 expecting AVXL to rise to within 12 months (a possible 611.99% upside). 6 analyst firms have reported ratings in the last year.
The latest analyst rating for Anavex Life Sciences (NASDAQ:AVXL) was provided by EF Hutton, and Anavex Life Sciences initiated their buy rating.
There is no last upgrade for Anavex Life Sciences
The last downgrade for Anavex Life Sciences Corp happened on December 6, 2022 when Cantor Fitzgerald changed their price target from $16 to $11 for Anavex Life Sciences Corp.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Anavex Life Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Anavex Life Sciences was filed on July 22, 2024 so you should expect the next rating to be made available sometime around July 22, 2025.
While ratings are subjective and will change, the latest Anavex Life Sciences (AVXL) rating was a initiated with a price target of $0.00 to $46.00. The current price Anavex Life Sciences (AVXL) is trading at is $6.46, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.